Windward Bio
Switzerland · Biopharma, Biotechnology, Health Care
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class
Key facts
- Headquarters
- Switzerland
- Employees
- 40
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- windwardbio.com
- Company page
Recent activity at Windward Bio
- : Windward Bio secures $165M in funding led by OrbiMed to advance its lead candidate WIN378 into Phase 3 and WIN027 into studies by Q4 2026.
- : Windward Bio raised $200M in a Series A funding round led by OrbiMed Novo Holdings and Blue Owl Healthcare Opportunities to develop a phase 2-ready monoclonal antibody for asthma and COPD.
- : Windward Bio announces $200M Series A financing to develop long-acting treatments for asthma and COPD.
Windward Bio funding history
| Date | Round | Amount |
|---|---|---|
| May 2026 | Funding Round | $165.0M |
| Jan 2025 | Series A | $200.0M |
Leadership
- Luca Santarelli, Founder, CEO and Chairman
- Michael Steininger, Senior Vice President & Head HR
- Omar Khwaja, Chief Medical Officer
- Kevin Harris, Chief Operating Officer
- Omar Khwaja, Chief Medical Officer
Verified email and direct lines for Windward Bio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Windward Bio in the news
Companies similar to Windward Bio
- Arecor Therapeutics PLC · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Apollomics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Day One Biopharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Cumulus Oncology · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Windward Bio: questions and answers
What does Windward Bio do?
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class
Where is Windward Bio headquartered?
Windward Bio is headquartered in Switzerland.
How many employees does Windward Bio have?
Windward Bio has about 40 employees.
Has Windward Bio raised funding?
Yes. Fundz has recorded 2 funding events for Windward Bio. The most recent, Funding Round of $165.0M, was in May 2026.
Who leads Windward Bio?
Luca Santarelli is a Founder, CEO and Chairman at Windward Bio.
What is the latest news on Windward Bio?
On May 05, 2026, Windward Bio secures $165M in funding led by OrbiMed to advance its lead candidate WIN378 into Phase 3 and WIN027 into studies by Q4 2026.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy